{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:54:57Z","timestamp":1790747697768,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Adult-onset immunodeficiency with anti\u2013interferon-\u03b3 autoantibodies (AIGA) is a rare acquired immunodeficiency increasingly recognized in East and Southeast Asia, characterized by disseminated infections with nontuberculous mycobacteria and other intracellular pathogens. Recent studies have refined our understanding of its immunopathogenesis, including HLA-linked susceptibility, epitope-specific neutralization of IFN-\u03b3, and molecular mimicry, while highlighting persistent gaps in diagnosis and treatment. This Perspective synthesizes emerging evidence into a clinically oriented framework spanning diagnosis, monitoring, and immunomodulatory therapy. We discuss functional confirmation of AIGA, repurposing of the QuantiFERON-TB platform as an accessible screening strategy, and quantitative titers and \u00b9\n                    <jats:sup>8<\/jats:sup>\n                    F-FDG PET as complementary biomarkers of disease activity and treatment response. We propose a clinical decision pathway in which refractory or progressive infection, rather than a fixed titer threshold, triggers immunomodulation, with rituximab and cyclophosphamide as the best-supported induction strategies, daratumumab reserved for refractory cases, and emerging AIGA-specific evidence supporting azathioprine for maintenance. Recognizing heterogeneous access to specialized testing and biologics across AIGA-endemic regions, we propose a resource-stratified approach integrating widely available markers with referral-based testing and resource-adapted treatment. We also highlight emerging antigen-specific strategies, including chimeric autoantibody receptor T cells engineered to eliminate autoantibody-producing B cells, as a future direction toward durable remission. Finally, we outline priorities for prospective validation and biomarker-guided therapy.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1964087","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:32Z","timestamp":1790744192000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-interferon-\u03b3 autoantibodies: immunopathogenesis, diagnostic innovation, and emerging therapeutic strategies in an adult-onset immunodeficiency"],"prefix":"10.3389","volume":"17","author":[{"given":"Chin-Shiang","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University","place":["Tainan, Taiwan"]},{"name":"Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine","place":["Charlottesville, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristine","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farha","family":"Naz","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine","place":["Charlottesville, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","article-title":"Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification","volume":"40","author":"Bousfiha","year":"2020","journal-title":"J ClinImmunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-020-02180-0","article-title":"Autoantibodies against cytokines: phenocopies of primary immunodeficiencies","volume":"139","author":"Ku","year":"2020","journal-title":"Hum Genet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1086\/380453","article-title":"Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity","volume":"38","author":"D\u00f6ffinger","year":"2004","journal-title":"Clin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1065","article-title":"Naturally occurring anti\u2013IFN-\u03b3 autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans","volume":"103","author":"H\u00f6flich","year":"2004","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.7.4769","article-title":"Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections","volume":"175","author":"Patel","year":"2005","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/cid\/ciz786","article-title":"Natural history and evolution of anti-interferon-\u03b3 autoantibody-associated immunodeficiency syndrome in Thailand and the United States","volume":"71","author":"Hong","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.05.007","article-title":"Anti-interferon-\u03b3 autoantibody-associated immunodeficiency","volume":"72","author":"Shih","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00933-2","article-title":"Anti-cytokine autoantibodies: mechanistic insights and disease associations","volume":"24","author":"Cheng","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-452482","article-title":"Anti-IFN-\u03b3 autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection","volume":"121","author":"Chi","year":"2013","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128481","article-title":"HLA-DRB1 and HLA-DQB1 are associated with adult-onset immunodeficiency with acquired anti-interferon-gamma autoantibodies","volume":"10","author":"Pithukpakorn","year":"2015","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaci.2015.09.018","article-title":"Anti-IFN-\u03b3 autoantibodies are strongly associated with HLA-DR*15:02\/16:02 and HLA-DQ*05:01\/05:02 across Southeast Asia","volume":"137","author":"Ku","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/nm.4158","article-title":"Identification of a major epitope by anti-interferon-\u03b3 autoantibodies in patients with mycobacterial disease","volume":"22","author":"Lin","year":"2016","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/1535370218764086","article-title":"Characterization of anti-interferon-\u03b3 antibodies in HIV-negative immunodeficient patients infected with unusual intracellular microorganisms","volume":"243","author":"Wipasa","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.06.029","article-title":"Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-\u03b3 autoantibodies in patients with disseminated nontuberculous mycobacterial infection","volume":"24","author":"Wu","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix372","article-title":"Repurposing QuantiFERON for detection of neutralizing interferon-\u03b3 autoantibodies in patients with nontuberculous mycobacterial infections","volume":"65","author":"Su\u00e1rez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6473629","article-title":"Intravenous cyclophosphamide therapy for anti-IFN-gamma autoantibody-associated Mycobacterium abscessus infection","volume":"2018","author":"Chetchotisakd","year":"2018","journal-title":"J Immunol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad676","article-title":"Efficacy of bortezomib for treating anti-interferon-gamma autoantibody-associated adult-onset immunodeficiency syndrome","volume":"78","author":"Angkasekwinai","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae708","article-title":"Utility of 18F-fluorodeoxyglucose positron emission tomography in evaluating disseminated nontuberculous Mycobacterial infection in patients with anti-interferon-\u03b3 autoantibodies","volume":"11","author":"Chuang","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051673","article-title":"Pathogen spectrum and immunotherapy in patients with anti-IFN-\u03b3 autoantibodies: a multicenter retrospective study and systematic review","volume":"13","author":"Qiu","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190502","article-title":"Anti-IFN-\u03b3 autoantibodies underlie disseminated Talaromyces marneffei infections","volume":"217","author":"Guo","year":"2020","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-395707","article-title":"Anti-CD20 (rituximab) therapy for anti-IFN-\u03b3 autoantibody-associated nontuberculous mycobacterial infection","volume":"119","author":"Browne","year":"2012","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-017-0425-3","article-title":"Rituximab restores IFN-\u03b3-STAT1 function and ameliorates disseminated Mycobacterium avium infection in a patient with anti-interferon-\u03b3 autoantibody","volume":"37","author":"Koizumi","year":"2017","journal-title":"J ClinImmunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1086","article-title":"Daratumumab (anti-CD38) for treatment of disseminated nontuberculous mycobacteria in a patient with anti-Interferon-\u03b3 autoantibodies","volume":"72","author":"Ochoa","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B24","article-title":"Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases","volume":"34","author":"Alexander","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103623","article-title":"Management of infectious risk of daratumumab therapy in multiple myeloma: a consensus-based position paper from an ad hoc Italian expert panel","volume":"172","author":"Girmenia","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmab039","article-title":"Application of QuantiFERON ELISA for detection of interferon-gamma autoantibodies in adult-onset immunodeficiency syndrome","volume":"53","author":"Khositnithikul","year":"2022","journal-title":"Lab Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215581","article-title":"Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-\u03b3 autoantibodies","volume":"14","author":"Angkasekwinai","year":"2019","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0344248","article-title":"Correlation between clinical disease activity and interferon-\u03b3 autoantibody titers measured by inhibitory ELISA, and inflammatory biomarkers in adult-onset immunodeficiency associated with anti-interferon-\u03b3 autoantibodies","volume":"21","author":"Teepapan","year":"2026","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa035","article-title":"Prospective pilot study of cyclophosphamide as an adjunct treatment in patients with adult-onset immunodeficiency associated with anti-interferon-\u03b3 autoantibodies","volume":"7","author":"Laisuan","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12879-026-12581-7","article-title":"Azathioprine for remission maintenance in anti-interferon-\u03b3 autoantibody-associated immunodeficiency syndrome- a retrospective single-center cohort study","volume":"26","author":"Laisuan","year":"2026","journal-title":"BMC Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated Vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/ar3901","article-title":"B lymphocyte-typing for prediction of clinical response to rituximab","volume":"14","author":"Brezinschek","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.celrep.2019.06.066","article-title":"Single-cell analysis suggests that ongoing affinity maturation drives the emergence of pemphigus vulgaris autoimmune disease","volume":"28","author":"Cho","year":"2019","journal-title":"Cell Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02221","article-title":"CD27+CD38hi B cell frequency during remission predicts relapsing disease in granulomatosis with polyangiitis patients","volume":"10","author":"von Borstel","year":"2019","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13075-024-03297-7","article-title":"Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis","volume":"26","author":"Pollastro","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adm8186","article-title":"Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN-\u03b3","volume":"10","author":"Peng","year":"2025","journal-title":"Sci Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J Autoimmun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa117","article-title":"Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results","volume":"36","author":"Kraaij","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"B46","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13063-023-07218-y","article-title":"A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol","volume":"24","author":"McClure","year":"2023","journal-title":"Trials"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1964087\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:33Z","timestamp":1790744193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1964087\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2026.1964087"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1964087","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1964087"}}